[Administration of micronized palmitoylethanolamide (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis: preliminary results].
OBJECTIVE
Aim of the study was to evaluate the effectiveness of micronized palmitoylethanolamide (PEA)-transpolydatin in the treatment of chronic pelvic pain in women affected by endometriosis.


METHODS
Twenty-four patients with suspected endometriosis affected by severe pelvic pain were enrolled. All patients received two tablets a day of PEA 400 mg and 40 mg polydatin for 90 days consecutively. A Visual Analogic Scale was used for the assessment of the severity of global pain, dysmenorrhea, dyspareunia, dysuria and dischezia. A second questionnaire was submitted to patients to assess the quality of life. The compilation of a diary lead us to evaluate the monthly assumption of any painkillers. Patients were evaluated at the begin of the treatment and then monthly until the end of the study (90 days). The statistical analysis was performed by using the ANOVA for the analysis of variance.


RESULTS
Statistically significant results were found in relation to pelvic pain, dysmenorrhea and dyspareunia compared to the initial evaluation of patients. Results related to dysuria and dischezia were not statistically significant (P>0.05). The decrease in pelvic pain leads to an improvement of the quality of life of patients. A decreased assumption of nonsteroidal anti-inflammatory drugs (NSAIDs) was also observed.


CONCLUSIONS
PEA could be considered an effective supplement to conventional analgesic therapies in the management of pelvic pain related to endometriosis.
Dipartimento di Scienze Biomediche e Terapie Avanzate, Clinica Ginecologica e OstetricaUniversità degli Studi di Ferrara, Ferrara, Italia - roberto.marci@unife.it.
G
G
Lo Monte
I
I
Soave
R
R
Marci
D000328:Adult; D000577:Amides; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D059350:Chronic Pain / Q000188:drug therapy / Q000209:etiology / Q000523:psychology; D004338:Drug Combinations; D004412:Dysmenorrhea / Q000188:drug therapy / Q000209:etiology; D004414:Dyspareunia / Q000188:drug therapy / Q000209:etiology; D063388:Endocannabinoids / Q000008:administration & dosage / Q000627:therapeutic use*; D004715:Endometriosis / Q000150:complications*; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005960:Glucosides / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010169:Palmitic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D010316:Particle Size; D017699:Pelvic Pain / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D010865:Pilot Projects; D011788:Quality of Life; D013267:Stilbenes / Q000008:administration & dosage / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D055815:Young Adult
D000577:Amides; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D063388:Endocannabinoids; D004983:Ethanolamines; D005960:Glucosides; D010169:Palmitic Acids; D013267:Stilbenes; C550607:pelvilen; C005958:palmidrol; C058229:polydatin